Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
about
The effect of preoperative treatment of P2Y12 receptor antagonists on perioperative bleeding and mortality in patients treated with coronary artery bypass grafting (CABG)The effect of preoperative treatment of P2Y12 receptor antagonists on perioperative bleeding and mortality in patients treated with coronary artery bypass grafting (CABG)Antiplatelet therapy in acute coronary syndromes: focus on ticagrelorTicagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromesP2Y12-ADP receptor antagonists: Days of future and pastShould dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trialsComing safely to a stop: a review of platelet activity after cessation of antiplatelet drugsThe pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistanceTicagrelor: molecular discovery to clinical evidence: ticagrelor: a novel antiplatelet agentPharmacotherapy in the cardiac catheterization laboratory: evolution and recent developmentsG-protein-coupled receptors signaling pathways in new antiplatelet drug developmentA review of the mechanisms and effectiveness of dietary polyphenols in reducing oxidative stress and thrombotic riskManagement standards for stable coronary artery disease in India.Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).Safety and Efficacy of Intravenous Tirofiban as Antiplatelet Premedication for Stent-Assisted Coiling in Acutely Ruptured Intracranial Aneurysms.P2Y12 platelet receptors: importance in percutaneous coronary interventionThe clinical efficacy and safety evaluation of ticagrelor for acute coronary syndrome in general ACS patients and diabetic patients: A systematic review and meta-analysis.Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgeryNovel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.Antiplatelet drug interactions with proton pump inhibitorsAbciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectivesPharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.Southern Saskatchewan Ticagrelor Registry experience.Clinical importance of aspirin and clopidogrel resistanceTicagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics.A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCITicagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials.An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers.Clinical evidence of interaction between clopidogrel and proton pump inhibitorsA comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD studyOvercoming aspirin resistance with loading clopidogrel earlier in elective percutaneous coronary intervention.Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspectiveSignificance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease.Anti-platelet therapy: ADP receptor antagonists.
P2860
Q24187718-23BF3753-C3B4-4A61-B941-37AA6FDCD42CQ24197708-4BEA47F3-A0C8-4B88-8CAB-64F2E2A8FB7FQ24605508-BD311346-C0A5-475B-ABC6-2FC76772FCE6Q24631111-2BCE5522-EFB9-497C-9065-D2CCD7043B47Q26745619-B8FEAE08-0BCA-4331-88A0-4D8A6D74F429Q26782970-77DDC610-4741-4D13-A01F-3B8D4EAE86F5Q26795403-708BE8D4-91CE-4983-AC75-83D0C88D319DQ26801867-BCC1DBB3-9857-44E4-9740-45211289E712Q26824850-BDD9E51C-0F2F-412F-AAB9-6526F10E6EA1Q26829967-2A7844C1-4BDB-4B66-B413-6478240A9390Q26862694-FF263CBC-865F-44F7-8760-570CC7156914Q26864951-03089434-D80A-45F5-A953-6E57BC2D0795Q28301541-BBA74EE2-B48C-4ABA-A02A-3DAEFA692656Q30239853-20CFDC7D-F304-4C74-90DC-D79166023D95Q30821177-458C858E-9BD6-4FED-A67A-AD720A71567BQ30827217-B504547D-52C1-4CA2-9D08-663BF7DF5C8CQ33426776-55C9AFB3-7A76-494D-9E73-931E129E0E92Q33655109-1830C346-F3E1-4E80-A037-BD11345BB3D3Q33699370-29E285C9-EAF7-4428-A176-883C2B4B16C9Q33755419-64962FA7-4E1A-43F2-976C-F2783467367CQ33902628-0B4830BC-70ED-4EF8-9284-1BCFE338BCADQ33948811-A22F7DE4-1749-44D0-B090-7A22A0552A08Q33952693-8E73446D-1C3F-4D3A-AEA9-C793F7772717Q34019342-3096EF50-447B-4EE1-8FBC-E2CF9B090574Q34043989-6A85B9C8-4E95-4A62-BB06-7B5C29782D05Q34387201-1C7AA5E5-AAD8-4E33-A43B-A025C0FC7012Q34390050-6DFF20C1-6973-4268-9A17-91FBB8FABADFQ34404150-D113166F-1978-4AC1-A27E-D66597213F7FQ34716730-09ABADF4-E115-4910-9F60-4353DB730762Q34761979-899406B8-6CA4-4DF6-B3BD-688AFB86613EQ34805121-730CE9F2-CD6C-424D-9018-D1DD0E43BB89Q34990246-D74829D8-37E5-4DFA-8932-20CF0E745CF8Q34994015-D516CFC2-3351-4583-B76E-87B06AA75BFEQ34998679-C9699883-1790-430E-8736-62EED4A9E707Q35033722-A9E5CEE3-E9FA-453F-911A-5AA14C6BB1A2Q35126038-9A7989EF-4EEB-4A51-82DD-03B153593B4FQ35141555-8B8EB171-50F3-43DE-975A-447CB3168D70Q35174193-19D4E69F-916F-481B-BBB8-E7F91D3773C0Q35176063-C0E45F47-F613-4942-AC15-3EFD7641B691Q35278165-A305CC96-FE1F-486E-A56A-B313E7A7F5A5
P2860
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Randomized double-blind assess ...... sease: the ONSET/OFFSET study.
@ast
Randomized double-blind assess ...... sease: the ONSET/OFFSET study.
@en
Randomized double-blind assess ...... sease: the ONSET/OFFSET study.
@nl
type
label
Randomized double-blind assess ...... sease: the ONSET/OFFSET study.
@ast
Randomized double-blind assess ...... sease: the ONSET/OFFSET study.
@en
Randomized double-blind assess ...... sease: the ONSET/OFFSET study.
@nl
prefLabel
Randomized double-blind assess ...... sease: the ONSET/OFFSET study.
@ast
Randomized double-blind assess ...... sease: the ONSET/OFFSET study.
@en
Randomized double-blind assess ...... sease: the ONSET/OFFSET study.
@nl
P2093
P1433
P1476
Randomized double-blind assess ...... isease: the ONSET/OFFSET study
@en
P2093
Arun Karunakaran
Cheryl Wei
Cordel Parris
Dean J Kereiakes
Drew Purdy
Gary S Ledley
Kathleen Butler
Kevin P Bliden
Mark J Antonino
Paul A Gurbel
P304
P356
10.1161/CIRCULATIONAHA.109.912550
P407
P577
2009-11-18T00:00:00Z